• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Tempus, Cleveland Clinic Collaborate on Personalized Cancer Medicine Initiative

by Jasmine Pennic 09/14/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Cleveland_Clinic

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer.

As part of the research collaboration spanning multiple cancer subtypes, Tempus will provide molecular sequencing and analysis for patients enrolled in a precision oncology clinical study at Taussig Cancer Institute. This study is enrolling patients with advanced (metastatic or incurable) cancer who are running out of standard treatment options. The goal is to identify targeted therapies and/or clinical trials that a patient may be a good candidate for and to uncover patterns of clinical significance leading to more effective, personalized treatments.

“We are committed to supporting our clinicians and scientists in using complex information and advanced technology to care for our patients. Incorporating advanced genomic data may enhance our ability to analyze vast amounts of clinical and molecular data, as we seek to improve the treatment options for our patients,” said Dr. Brian J. Bolwell, chairman of Cleveland Clinic Taussig Cancer Institute, which is both an NCI-designated comprehensive cancer center and a top-ranked national provider of advanced cancer care to thousands of patients diagnosed with cancer every year. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cleveland Clinic, Personalized Cancer Medicine, Personalized Medicine, Precision Medicine Initiative, Precision Medicine Oncology, Tempus

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |